入排依据:The record describes a Phase 3 randomized trial in human oncology with a drug intervention. However, the provided abstract and metadata do not explicitly mention a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio. Therefore, the time-to-event criterion is not met.
摘要
摘要
The GLOW randomized double-blind phase 3 trial1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
KM 提取结果
0 个 Figure · 0 个 KM 面板